Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
Israeli biomedicine R&D company seeks investment.
|Total value of the target||N/A|
|Expected target net rate of return after deducting all taxes and fees||N/A|
|Validity period of pending order||365|
Assistant Manager, International Business Advisory
|Project highlights||patented - reduce the resistance of tumor - STAMP & TMEP|
The Israeli biomedicine R&D company has a project which has been developed and patented. This project aims to reduce the resistance of tumor to conventional treatment. Several diagnostic tests were used to decipher the specific tumor metabolic addiction profile (STMAP), considering the essential nutrients required for tumor proliferation and growth, and the tumor microenvironment profile (TMEP), the cellular environment in which the tumor exists. In addition, the project uses metabolic biomarkers to understand the molecular and cellular mechanisms driving tumor initiation, maintenance and expansion, combined with predictive (diagnostic) metabolic biomarkers to assist in matching targeted therapies (drugs and natural compounds). The company seeks investment for this project.
Enquire for more information about our services, and how we can help solve challenges for your organizationContact Us